In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to…
The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.
All people affected by TB have a right to benefit from scientific progress and to access the best-available short-course regimens for TB prevention and treatment. The 1/4/6x24 Campaign demands that countries and other duty bearers take action to implement the…
On March 24, World Tuberculosis (TB) Day offers an opportunity to take stock of global progress against the deadliest disease in human history. This year, we face a sobering reality: since the start of the COVID-19 pandemic, rates of TB infection and death are higher than they’ve been since the early 2000s, setting back an already woefully inadequate effort to end the disease.
Research into curing HIV infection is ever-changing as new discoveries are made and scientists report additional rare — but informative — cases of individuals likely cured of HIV.
Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.
Inspired by the legacy of Dr. Paul Farmer, the 1 / 4 / 6 x 24 Campaign calls for the “staff, stuff, space, systems and support” necessary to make groundbreaking short-course TB prevention and treatment regimens accessible to all who need them as a human right by the end of 2024.
The SMART4TB Consortium is calling for expressions of interest from multi-national community advisory boards (CAB) or similarly organized civil society organizations within three geographic focus areas to support community engagement in research in a new five-year research project funded by USAID.
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
On Tuesday, March 14 at 8:00 am ET, join Treatment Action Group (TAG) and Dr. Jennifer Furin for an overview of key results and breakdown of how they fit into the larger TB policy and research landscapes.